Effectiveness of Platinum-Based Chemotherapy in Patients With Metastatic Prostate Cancer: Systematic Review and Meta-analysis

Leal, Frederico; García‐Perdomo, Herney Andrés

doi:10.1016/j.clgc.2019.03.008

Cited by 18 publications

(15 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although platinum‐based chemotherapy is sequentially not used for the treatment of CRPC, it has been reported to be effective for some CRPC patients. In a systematic review, Leal and García‐Perdomo found that platinum‐based chemotherapy was effective for patients with CRPC to some extent, 1 and Aparicio et al . reported that patients with some variants of CRPC and an atypical and aggressive clinical course were characterized by sensitivity to platinum‐based chemotherapy 2 .…”

Section: Discussionmentioning

confidence: 99%

Prominent response to platinum‐based chemotherapy in a patient with BRCA2 mutant‐neuroendocrine prostate cancer and MDM2 amplification

et al. 2021

View full text Add to dashboard Cite

Introduction Genomic profiling provides useful information for diagnosis, treatment, and prognosis, and detection of certain defects, such as DNA repair gene aberrations or microsatellite instability, can possibly lead to optimal treatment, but this testing has not been widely used to inform prostate cancer treatment. Case presentation A 55‐year‐old man sequentially treated for prostate cancer was diagnosed as neuroendocrine prostate cancer from prostate specimens resected because of urinary retention. Subsequently, he received five cycles of platinum‐based chemotherapy in total and responded well. We also performed next‐generation sequencing of a sample from the prostate specimen and identified a breast cancer susceptibility gene mutation with Murine Double Minute 2 amplification and loss of heterozygosity in retinoblastoma 1. Conclusion We report a neuroendocrine prostate cancer patient with Murine Double Minute 2 amplification who experienced an aggressive course and for whom platinum‐based chemotherapy was effective, and one of the reasons for the good response might be the breast cancer susceptibility gene mutation.

show abstract

Section: Discussionmentioning

confidence: 99%

Prominent response to platinum‐based chemotherapy in a patient with BRCA2 mutant‐neuroendocrine prostate cancer and MDM2 amplification

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Unfortunately, very few therapeutic options are available to patients progressing to taxanes, although platinum-based treatments have demonstrated a limited benefit in some patients. Modest response rates have been observed with single-drug platinum-based regimens, but more encouraging results have been obtained with platinum/taxane combinations [ 20 , 21 ]. Of note, Corn and colleagues suggested that cabazitaxel plus carboplatin is well tolerated and confers superior progression-free survival (PFS) and response rate (RR) than cabazitaxel alone in docetaxel-resistant mCRPC patients [ 22 ].…”

Section: Current Treatment Options For Metastatic Castration-resistant Prostate Cancer (Mcrpc)mentioning

confidence: 99%

Immune Checkpoint Inhibitors: A Promising Treatment Option for Metastatic Castration-Resistant Prostate Cancer?

Porras

Pardo

Notario

et al. 2021

IJMS

View full text Add to dashboard Cite

Since 2010, several treatment options have been available for men with metastatic castration-resistant prostate cancer (mCRPC), including immunotherapeutic agents, although the clinical benefit of these agents remains inconclusive in unselected mCRPC patients. In recent years, however, immunotherapy has re-emerged as a promising therapeutic option to stimulate antitumor immunity, particularly with the use of immune checkpoint inhibitors (ICIs), such as PD-1/PD-L1 and CTLA-4 inhibitors. There is increasing evidence that ICIs may be especially beneficial in specific subgroups of patients with high PD-L1 tumor expression, high tumor mutational burden, or tumors with high microsatellite instability/mismatch repair deficiency. If we are to improve the efficacy of ICIs, it is crucial to have a better understanding of the mechanisms of resistance to ICIs and to identify predictive biomarkers to determine which patients are most likely to benefit. This review focuses on the current status of ICIs for the treatment of mCRPC (either as monotherapy or in combination with other drugs), mechanisms of resistance, potential predictive biomarkers, and future challenges in the management of mCRPC.

show abstract

“…A systematic search on electronic databases evaluated the role of platinum compounds for mCRPC and suggested a statistically significant increase in both clinical as well biochemical response when adding platinum compounds to chemotherapy. 38 Similarly, oral cyclophosphamide was favored by 64.47% of the panelists. A comprehensive literature search was performed and concluded that it is active in the treatment for CRPC even among patients previously treated with chemotherapy, including docetaxel, yielding symptomatic and objective responses.…”

Section: Treatment Recommendationsmentioning

confidence: 99%

Consensus on the Treatment and Follow-Up for Metastatic Castration-Resistant Prostate Cancer: A Report From the First Global Prostate Cancer Consensus Conference for Developing Countries (PCCCDC)

Maluf

Pereira²,

Silva³

et al. 2021

JCO Global Oncology

View full text Add to dashboard Cite

PURPOSE To present a summary of the recommendations for the treatment and follow-up for metastatic castration-resistant prostate cancer (mCRPC) as acquired through a questionnaire administered to 99 physicians working in the field of prostate cancer in developing countries who attended the Prostate Cancer Consensus Conference for Developing Countries. METHODS A total of 106 questions out of more than 300 questions addressed the use of imaging in staging mCRPC, treatment recommendations across availability and response to prior drug treatments, appropriate drug treatments, and follow-up, and those same scenarios when limited resources needed to be considered. Responses were compiled and the percentages were presented by clinicians to support each response. Most questions had five to seven relevant options for response including abstain and/or unqualified to answer, or in the case of yes or no questions, the option to abstain was offered. RESULTS Most of the recommendations from this panel were in line with prior consensus, including the preference of a new antiandrogen for first-line therapy of mCRPC. Important aspects highlighted in the scenario of limited resources included the option of docetaxel as treatment preference as first-line treatment in several scenarios, docetaxel retreatment, consideration for reduced doses of abiraterone, and alternative schedules of an osteoclast-targeted therapy. CONCLUSION There was wide-ranging consensus in the treatment for men with mCRPC in both optimal and limited resource settings.

show abstract

Effectiveness of Platinum-Based Chemotherapy in Patients With Metastatic Prostate Cancer: Systematic Review and Meta-analysis

Cited by 18 publications

References 76 publications

Prominent response to platinum‐based chemotherapy in a patient with BRCA2 mutant‐neuroendocrine prostate cancer and MDM2 amplification

Prominent response to platinum‐based chemotherapy in a patient with BRCA2 mutant‐neuroendocrine prostate cancer and MDM2 amplification

Immune Checkpoint Inhibitors: A Promising Treatment Option for Metastatic Castration-Resistant Prostate Cancer?

Consensus on the Treatment and Follow-Up for Metastatic Castration-Resistant Prostate Cancer: A Report From the First Global Prostate Cancer Consensus Conference for Developing Countries (PCCCDC)

Contact Info

Product

Resources

About